Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA^® (Pembrolizumab) in Combination with LYNPARZA^® (Olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility

Merck announced that it will stop the Phase II KEYLYNK-010 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide.